Discover
AVTE
Aerovate Therapeutics, Inc.
2.68
undefined x undefined
undefined x undefined
bid
ask
+
0.00
0.00%
04:00 PM
| Ytd | ||
| 1y |
2.63
day range
2.77
52 week range
| Open | 2.66 | Prev Close | 2.68 | Low | 2.63 | High | 2.77 | Mkt Cap | N/A |
| Vol | 981.80K | Avg Vol | 0.00 | EPS | N/A | P/E | N/A | Forward P/E | -2.60 |
| Beta | N/A | Short Ratio | 0.98 | Inst. Own | 102.17% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | N/A | 200-d Avg | N/A | 1yr Est | 2.33 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-12 | 2024-09 | -0.59 | -0.56 | 0.03 | 5.08% |
| 2024-08-12 | 2024-06 | -0.76 | N/A | N/A | N/A |
| 2024-08-12 | 2024-06 | -0.76 | -0.86 | -0.1 | -13.16% |
| 2024-05-13 | 2024-03 | -0.74 | N/A | N/A | N/A |
| 2024-05-13 | 2024-03 | -0.74 | -0.83 | -0.09 | -12.16% |
| 2024-03-25 | 2023-12 | -0.68 | -0.74 | -0.06 | -8.82% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-06-18 | Evercore ISI Group | Downgrade | Outperform | In-Line |
| 2024-06-18 | Guggenheim | Downgrade | Buy | Neutral |
| 2024-06-18 | Wells Fargo | Downgrade | Overweight | Equal-Weight |
| 2024-06-18 | TD Cowen | Downgrade | Buy | Hold |
| 2024-06-17 | Jefferies | Downgrade | Buy | Hold |
| 2024-06-17 | BTIG | Downgrade | Buy | Neutral |
Profile
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-07-31 | DAKE BENJAMIN T | President | 14.25K | Conversion of Exercise of derivative security |
| 2024-06-13 | ELDRIDGE GEORGE ARTHUR | Chief Financial Officer | 5.02K | Conversion of Exercise of derivative security |
| 2024-06-12 | GILLIES HUNTER C | Officer | 5.60K | Conversion of Exercise of derivative security |
| 2024-04-08 | GRAYZEL DAVID S | Director | 0.00 | Sale |
| 2024-02-04 | NIVEN RALPH W | Officer | 1.61K | Conversion of Exercise of derivative security |
| 2024-05-15 | NOYES TIMOTHY P. | Chief Executive Officer | 0.00 | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | RA Capital Management, L.P. | 9.19M | 23.90M | 31.83% |
| 2024-09-29 | Sofinnova Investments, Inc. | 3.76M | 9.77M | 13.02% |
| 2024-09-29 | TCG Crossover Management, LLC | 2.24M | 5.83M | 7.76% |
| 2024-09-29 | Atlas Venture Life Science Advisors, LLC | 1.80M | 4.68M | 6.23% |
| 2024-09-29 | Deerfield Management Company, L.P. (Series C) | 1.41M | 3.67M | 4.89% |
| 2024-09-29 | Vanguard Group Inc | 1.15M | 2.99M | 3.99% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 531.54K | 1.38M | 1.84% |
| 2024-10-30 | iShares Russell 2000 ETF | 450.26K | 1.17M | 1.56% |
| 2024-09-29 | Vanguard Variable Insurance Fund-Small Company Growth | 290.43K | 755.12K | 1.01% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 202.52K | 526.55K | 0.70% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 135.61K | 352.59K | 0.47% |
| 2024-10-30 | iShares Russell 2000 Growth ETF | 111.78K | 290.63K | 0.39% |
Dividend
| Dividend | Date |
|---|---|
| 2.4 | 2025-04-29 |
Split
| Split | Date |
|---|---|
| 1 : 35 | 2025-04-29 |